Phase II Clinical Study of PD-1 Monoclonal Antibody Combination With Autologous Cytokine-induced Killer Cell Immunotherapy in the Second-line Treatment of Metastatic Clear Cell Renal Cell Carcinoma
Latest Information Update: 07 Jul 2022
At a glance
- Drugs Camrelizumab (Primary) ; Cytokine-induced killer cell therapy (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 05 Jul 2020 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.
- 05 Jul 2020 Planned primary completion date changed from 1 Jun 2021 to 1 Jun 2022.
- 18 Jun 2019 New trial record